Mammoth Biosciences Stock
CRISPR-Based Disease Detection Platform
Sign up today and learn more about Mammoth Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Mammoth Biosciences Stock
Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Mammoth aims to discover new types of CRISPR systems that could be used to solve specific biological problems.
Mammoth Biosciences was founded by Janice Chen in 2017 and is based in San Francisco, California. Notable investors include NFX, Mayfield Fund, and Decheng Capital.
Investors
aMoon Fund
Decheng Capital
Mayfield Fund
Lyft, Jawbone, Tonal, Alchemy, Grove Collaborative, Outreach, HashiCorp, MapR Technologies, Fungible, Versa Networks
Pacific 8 Ventures
Plum Alley
Verily
Funding History
| July 2018 | $18.1M |
|---|---|
| January 2020 | $7.4M |
| January 2020 | $36.8M |
| May 2020 | $748K |
| May 2020 | $44.4M |
| July 2021 | $100M |
| July 2021 | $50.0M |
Management
Chief Executive Officer
Trevor Martin
Chief Financial Officer
Elaine Sun
Press
biospace - Mar, 23 2022
Mammoth Biosciences Announces Key Leadership Appointmentsmarketwatch - Jan, 10 2022
Bayer to Collaborate on Gene Editing Technology With Mammoth Biosciencesjdsupra - Oct, 29 2021
Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systemsnews - Oct, 5 2021
NFX Closes On Pre-seed And Seed Fund 3 At $450MTechCrunch - Sep, 9 2021
Breakout ‘CRISPR platform’ company Mammoth Biosciences is officially a unicorngenomeweb - Sep, 9 2021
Mammoth Biosciences Raises $195M in Two Financing Rounds, Achieves Unicorn StatusTechCrunch - Aug, 12 2020
Mammoth Biosciences lands exclusive license to new CRISPR proteins that could boost gene editing precisionnews - May, 20 2020
Consumer COVID-19 Tests Closer To Reality Under Mammoth Biosciences/GSK PartnershipTechCrunch - May, 20 2020
Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 testTechCrunch - Jan, 30 2020
Mammoth Biosciences aims to be Illumina for the gene editing generationTechCrunch - Mar, 14 2019
Mammoth Biosciences adds the final piece of the CRISPR diagnostics puzzle to its toolkitTechCrunch - Sep, 4 2018
These two CRISPR experts are coming to Disrupt SF 2018GenomeWeb - May, 9 2018
Mammoth Biosciences Developing CRISPR-Based Disease Detection for At-Home, Hospital UseTechCrunch - Apr, 26 2018
Mammoth Biosciences launches a CRISPR-powered search engine for disease detectionSTAT - Feb, 15 2018
With new CRISPR inventions, its pioneers say, you ain't seen nothin' yetTechCrunch - Sep, 14 2017
NFX Guild just showed 14 new companies to top investors in its latest demo dayEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
